CTOs on the Move

Cytrellis

www.cytrellis.com

 
Cytrellis is a medical technology company dedicated to the development and commercialization of first-in-class aesthetic devices which emphasize safety, efficacy, and improved quality of life for our patients. Cytrellis` first product, the ellacor® System with Micro-Coring™ Technology, is indicated for use by medical professionals for the treatment of moderate to severe wrinkles in the mid to lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV. Ellacor provides aesthetic practitioners with an unprecedented ability to improve age-related changes in skin and to help restore youthful beauty.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Shivkumar Sabesan
Chief Technology Officer Profile

Funding

Cytrellis raised $28.5M on 06/05/2018

Similar Companies

NIHON KOHDEN CORPORATION

NIHON KOHDEN CORPORATION is a Foothill Ranch, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Minimax

Minimax is a West Hempstead, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novadaq

Enabling surgeons with clinically-relevant, innovative fluorescence imaging solutions to enhance the lives of patients and their surgeons, while reducing health care costs, is Novadaq’s global mission. SPY fluorescence imaging technology provides surgeons with real-time visualization, leading to improved outcomes and reduced costs without exposing the patient to harmful ionizing radiation or contrast dye toxicity. More than 130 peer-reviewed publications demonstrate that the use of SPY during complex surgery, leads to fewer post-operative complications and lower hospital costs. The SPY Imaging System is United States Food and Drug Administration (“FDA”) 510(k) cleared for use in seven surgical specialties. The endoscopic version of SPY called PINPOINT®, combines the capabilities of SPY Imaging with high definition (“HD”) visible light visualization offered by conventional endoscopes. Our unique business model of partnering with market-leading companies to drive adoption of our fluorescence imaging technology, while building our own commercial infrastructure is the cornerstone of our corporate strategy for growth.

GlySens

GlySens Incorporated is a privately held corporation devoted to developing the world`s first truly long term continuous glucose monitoring system. Our goal: to enable easy, unobtrusive, worry-free diabetes control that empowers users by providing the information they need to optimize care, while freeing them to live life on their own terms.